MENU
NO | NOK
-
-
-
- Forum Labo 2025
- Advanced Therapies Week (ATW) 2025
- SLAS Europe 2025
- Medlab Middle East 2025
- Biologics World Nordics 2025
- Bioprocessing Summit Europe 2025
- BioProcess International Europe 2025
- ASIA LABEX: The Lab Show 2025
- SLAS International 2025
- ISEV 2025
- Future Labs Live 2025
- DataHow Symposium 2025
- Cell 2025
-
-
-
- Forum Labo 2025
- Advanced Therapies Week (ATW) 2025
- SLAS Europe 2025
- Medlab Middle East 2025
- Biologics World Nordics 2025
- Bioprocessing Summit Europe 2025
- BioProcess International Europe 2025
- ASIA LABEX: The Lab Show 2025
- SLAS International 2025
- ISEV 2025
- Future Labs Live 2025
- DataHow Symposium 2025
- Cell 2025
NO | NOK
-
- Benchtop Centrifuges
- Floor-Standing Centrifuges
- Refrigerated Centrifuges
- Microcentrifuges
- Multipurpose Centrifuges
- High-Speed Centrifuges
- Ultracentrifuges
- Concentrator
- IVD Products
- High-Speed and Ultracentrifuge Consumables
- Centrifuge Tubes
- Centrifuge Plates
- Device Management Software
- Sample and Information Management
No results found
Search Suggestions

Webinar
Controlling Expansion and Cardiomyogenic Differentiation
During this webinar we present how hPSC expansion as matrix-independent aggregates in suspension culture (3D) was successfully combined with cardiomyogenic differentiation.
To harness the potential of human pluripotent stem cells (hPSCs), abundant provision of their differentiated progenies is required. During this webinar we present how hPSC expansion as matrix-independent aggregates in suspension culture (3D) was successfully combined with cardiomyogenic differentiation. A multi-well screening approach was scaled-up to stirred-tank bioreactors applying controlled feeding strategies (Batch and Cyclic Perfusion) followed by differentiation.
Optimized conditions in 100 mL cultivations enabled the production of 40 million cardiomyocytes (>80% purity), the majority of which displayed ventricular-like action potentials and were directly applicable for bioartificial cardiac tissue formation, a potential strategy for heart repair, drug discovery and safety pharmacology.
This webinar took place on June 9, 2015.
Optimized conditions in 100 mL cultivations enabled the production of 40 million cardiomyocytes (>80% purity), the majority of which displayed ventricular-like action potentials and were directly applicable for bioartificial cardiac tissue formation, a potential strategy for heart repair, drug discovery and safety pharmacology.
This webinar took place on June 9, 2015.
Key Learning Objectives:
- Learn about challenges in up-scaling hPSC suspension cultures and the latest achievements using stirred-tank bioreactors.
- Understand the role of bioreactor design for cell aggregate formation and
- Learn about tools and process parameters for controlled cultivation of stem cell cultures.
Read more
Read less
Register and watch recording now!
Read more
Read less